

## COVID-19 Pneumonia and the Administration of Antibiotics if Needed

Abdulfatah Saed

Higher Institute of Medical Technology - Bani Waleed/ Libya

\*Corresponding author: [ftahsaad@gmail.com](mailto:ftahsaad@gmail.com)

### Article history

Received: July 16, 2022

Accepted: July 22, 2022

Published: August 02, 2022

### Keywords:

COVID-19

Antibiotics

medicine

**Abstract:** Everyone has developed a habit of discussing COVID-19. The COVID-19 epidemic has made respiratory sickness, including infection, pneumonia, and mortality, front-page news. Many of us have been waiting for and fearing the next global respiratory pandemic. 2019 marks a century since the end of the 1918 H1N1 influenza A pandemic, and many were amazed that we had gone so long without a comparable recurrence. Even though there have since been other global pandemics, the 1918 influenza pandemic stood out because it lasted for more than a year, affected approximately one-third of humanity, and claimed the lives of more than 50 million people.

**Cite this article as:** A. Saed, "COVID-19 Pneumonia and the Administration of Antibiotics if Needed," *African Journal of Advanced Pure and Applied Sciences (AJAPAS)*, Vol. 1, Issue 3, pp. 55-57, 2022.

Publisher's Note: African Academy of Advanced Studies – AAAS stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee African Journal of Advanced Pure and Applied Sciences (AJAPAS), Libya. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Bacterial superinfections may explain some of the lethality of H1N1. According to abundant statistics, the majority of deaths caused by influenza during the 1918 pandemic were due to subsequent bacterial pneumonia. when both innate and adaptive host defenses against microorganisms are compromised by a prior viral infection, such as COVID-19 or influenza, *Streptococcus pneumoniae*, *Staphylococcus aureus*, or other colonizing bacteria exploit this temporary compromise of a physical and immunological barrier to cause secondary bacterial pneumonia, which can be fatal in people with pre-existing comorbidities and previously healthy people. Although data on bacterial superinfections in COVID-19 pneumonia are still being collected, a link has been established between the detection of bacterial products in blood and illness severity in COVID-19 patients. Detecting coinfections is difficult even under the best of conditions, and because there is a desire to avoid diagnostic procedures and limit COVID-19 exposure to health-care professionals, diagnosing possible bacterial superinfections during COVID-19 has proved difficult

Biomarkers related with COVID-19 severity might help predict prognosis. COVID-19 disease development is aided by hyperinflammation, and an inflammatory cytokine storm can worsen the condition. 3 Despite the fact that many serum biomarkers lack specificity, elevated procalcitonin concentrations have been studied as a specific bacterial distinction from viral response to bacterial respiratory tract illness. Despite a variety of cutoffs used, there seems to be a significant relationship between higher procalcitonin concentrations and rising COVID-19 disease severity based on growing report and dataset.

Antibiotics may safely and effectively treat the majority of bacterial pneumonias if they are identified in time, and COVID-19. Patients frequently take broad-spectrum antibiotics. On the other side, the use of antibiotics encourages the development of bacteria that are resistant to them. Antibiotic resistance is a global epidemic that causes millions of antibiotic-resistant infections and more than 700,000 fatalities each year. It is not merely an

existential threat. According to a 2019 warning from the UN Interagency Coordination Group on Antimicrobial Resistance, antibiotic-resistant infections could kill 10 million people annually by 2050 and cause such severe economic harm that up to 24 million people could fall into extreme poverty as a result of antimicrobial resistance. There are fears that increased antibiotic use during the COVID-19 pandemic would aggravate the present worldwide antimicrobial resistance pandemic. When faced with severely ill and hospitalized patients, however, healthcare professionals will and should err on the side of broad-spectrum antibiotics, both as recommended and empirical therapy, when the diagnosis of a likely bacterial superinfection is disputed. In an effort to save the lives of COVID-19 patients, physicians are becoming less likely to follow recommended antibiotic stewardship practices.

The use of antibiotics saves lives. The availability of antibiotics is crucial, yet despite increased antibiotic usage, many people in places with limited resources lack access to medicines. Antibiotic resistance kills more individuals than by antibiotic resistance. It is crucial to assess how well antibiotics are used to treat pneumonia in order to manage the problems with antimicrobial resistance and ensure that patients have access to life-saving drugs. However, it is still difficult to define what acceptable signifies because it is still very difficult to diagnose pneumonia. A greater knowledge of and ability to forecast the severity of the COVID-19 sickness is necessary for effective management of this lethal respiratory epidemic. A multitiered COVID-19 diagnostic strategy that incorporates quick, point-of-care host immune testing is being advocated to help identify patients who are at risk for illness and progression. Making plans for the present and next pandemics may be possible with the help of a platform like this. If doctors can reliably and quickly anticipate the likelihood of disease and progression, in which infected COVID-19 patients acquire severe pneumonia and disease, it should be simpler for them to risk-stratify patients and make sure they have access to the best care and resources.

On November 12, World Pneumonia Day, it is appropriate to raise awareness of the need for improved research and development of diagnostics and prognostics for pneumonia in general and COVID-19 in particular. Antibiotics, which were not accessible during the 1918 H1N1 influenza pandemic, undoubtedly saved hundreds of lives in seriously sick COVID-19 patients.

## References

- [1] Ibrahim, Hamza Khalifa, Alla Abdulmutalib Mohammed, and Ola Adrees Omar. "Effects of Antibiotics (Ciprofloxacin–Augmentin–Gentamicin–Norfloxacin–Ampicillin) which are used for Treatment of Urinary Tract Infections in Female Patients." V, Issue 10 (2018).
- [2] Ibrahim, Hamza Khalifa. "ANTIBIOTICS EFFECTS (CIPROFLOXACIN-AUGMENTIN-GENTAMICIN-NORFLOXACIN-AMPICILLIN) ON BACTERIA (E. COLI STAPH ALBUS AND KLEBSIELLA).".
- [3] Ibrahim, Hamza Khalifa, et al. "The Most Commonly Used Drugs in Combating the Emerging Corona Virus Disease (Covid-19)."
- [4] Ibrahim, H. K., Ahseen, N. A., Ahmed, T. I., Ahseen, N. A., Al-Awkally, N.-A. M., & Yousuf, A. (2022). Evaluation of dexamethasone effects in COVID-19 treatment. *International Journal of Health Sciences*, 6(S1), 546-554. <https://doi.org/10.53730/ijhs.v6nS1.4799>
- [5] Hamza Khalifa Ibrahim, and Ibrahim M Bendala, Abdulfatah Saed, Naser Ramdan R, Abdulhadi Masoud Alsanousi Aljadi, Dr. Osama Lamma "COVID-19: MOST EFFECTIVE DRUG TREATMENT", 5. INTERNATIONAL PARIS CONFERENCE ON SOCIAL SCIENCES, February 7-8, 2021 Paris – FRANCE.
- [6] Al-Awkally, Noor Alhooda M., et al. "Study of antibiotic sensitivity pattern in urinary tract infection." *International Journal of Health Sciences* 6 (2022): 8896-8913.
- [7] Ibrahim, Hamza Khalifa, et al. "Covid-19 Pandemic and Its Impact on Psychological Distress, Malignancy and Chronic Diseases: A Scoping Review." *Eduvest-Journal Of Universal Studies* 2.5 (2022): 1017-1021.
- [8] Khalifa, Hamza, Noor Alhooda Milood Al-Awkally, and Salwa Muftah Eljamay. "Oral Delivery of Biologics: Recent Advances, Challenges, and Future Perspectives." *African Journal of Advanced Pure and Applied Sciences (AJAPAS)* (2022): 1-6.

- [9] Fakron, Abdmanam, et al. "Risk Factors for Ciprofloxacin and Gentamycin Resistance among Gram Positive and Gram Negative Bacteria Isolated from Community-Acquired Urinary Tract Infections in Benghazi city." *Scientific Journal for the Faculty of Science-Sirte University* 2.1 (2022): 76-87.
- [10] Muthanna, Fares M., et al. "C-reactive protein in patients with COVID-19: A scoping review." *International Journal of Health Sciences* 6 (2022): 1610-1620.
- [11] Ibrahim, Hamza Khalifa, et al. "Evaluation of Dexamethasone Effects in COVID-19 Treatment."
- [12] Khan, M. Salman, et al. "Effect of Covid 19 on Poultry Industry." *African Journal of Advanced Pure and Applied Sciences (AJAPAS)* (2022): 23-25.
- [13] Hamza, Muhammad, and Hamza Khalifa Ibrahim. "Effect of Avian Corona Virus; A letter to Editor." *Brilliance: Research of Artificial Intelligence* 2.2 (2022): 75-76.
- [14] Arif, S., Zia, T., Qayyum, Z., Mustafa, G., Ateeq, M., Farhad, S., ... & Muthanna, F. M. (2022). Prevalence and Risk Factors of Covid-19 Mortality and its Impact on Social Life of Pakistani Population. *Pakistan Journal of Medical & Health Sciences*, 16(03), 800-800.
- [15] Arif, S., Zia, T., Mustafa, G., Qayyum, Z., Ateeq, M., Faiz, M. J., ... & Ullah, I. (2022). Knowledge, Attitude and Practices of Medical Students Regarding Covid-19, Pakistan. *Pakistan Journal of Medical & Health Sciences*, 16(03), 783-783.
- [16] Muthanna, F. M., & Samad, A. (2022). Covid-19 Pandemic (Incidence, Risk factors and Treatment). *BULLET: Jurnal Multidisiplin Ilmu*, 1(01), 46-48.
- [17] Shah, M. A., Kassab, Y. W., Anwar, M. F., Al Dahoul, H. K., Menon, S., Kaur, H. J., ... & Searan, W. M. (2019). Prevalence and associated factors of urinary tract infections among diabetic patients. *Health Science Journal*, 13(2), 1-5.